Findings from epidemiological studies over the past 30 years have shown that visceral
adipose tissue, accurately measured by CT or MRI, is an independent risk marker of …

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with a worldwide
prevalence of 25%. In the United States, NAFLD and its subtype, nonalcoholic …

The Mediterranean diet (MD) may provide metabolic benefits but no systematic review to
date has examined its effect on a multitude of outcomes related to metabolic health. This …

Metabolic syndrome (MetS) is a bunch of metabolic defects comprising hypertension, insulin
resistance, visceral obesity, fatty liver, and atherogenic cardiovascular diseases. Lifestyle …

Human organoid systems recapitulate in vivo organ architecture yet fail to capture complex
pathologies such as inflammation and fibrosis. Here, using 11 different healthy and …

Nonalcoholic fatty liver disease (NAFLD) affects around a quarter of the global population,
paralleling worldwide increases in obesity and metabolic syndrome. NAFLD arises in the …

Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MS) are two different
entities sharing common clinical and physio-pathological features, with insulin resistance …

Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) are both
manifestations of end-organ damage of the metabolic syndrome. Through multiple …

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the Western
world, strongly associated with insulin resistance and the metabolic syndrome. Nonalcoholic …

Non-alcoholic fatty liver disease (NAFLD) has become one of the most frequent chronic liver
diseases in the Western society and its prevalence is likely to rise even further. An …